Programme (PDF) - (NCRI) Cancer Conference 2013 - National ...

14.30 – 15.30 Workshops
• How to become a post-doc or a clinician scientist
• Prioritising research in the networks
• Randomised controlled trials in end of life care
• Tumour banking and access to samples debate
15.40 – 17.55 Parallel sessions
• From the genome to the clinic: connecting data
for better health
• Hypoxia and the Warburg effect
• Improving patient care: quality assurance of
psychological care
• Infection and cancer: epidemiology, biology and
prevention
• Lung cancer
• New strategies for improving prognosis in breast
cancer
• Paediatric tumours
• PET Imaging
• Proffered paper highlights 1
• Targeting mitosis
• Upper gastrointestinal cancers
18.00 – 18.30 Refreshment Break
18.30 – 19.50 Clinical trials showcase
Hosted by David Cameron
National Cancer Research Network, UK
• Phase II trial of the oral PARP inhibitor
olaparib in BRCA-deficient advanced
breast cancer
Andrew Tutt
Breakthrough Breast Cancer Research Unit, King’s College
London Guy’s Hospital, London, UK
• MRC OV05/EORTC 55955 Ovarian Cancer
Trial of early treatment of relapse based
on CA125 level alone versus delayed
treatment
Gordon Rustin
Mount Vernon Cancer Centre, Northwood, UK
• Results from the MRC Coin trial of firstline
therapy for advanced colorectal
cancer (aCRC)
Tim Maughan
Cardiff University, UK
• Results of a phase III multi-centre
randomised controlled trial of intensity
modulated (IMRT) vs conventional
radiotherapy (RT) in head and neck cancer
(PARSPORT: ISRCTN48243537;
CRUK/03/005)
Christopher Nutting
Royal Marsden NHS Foundation Trust and The Institute of
Cancer Research, London, UK
5